Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease : A Consensus-based Position Paper From an ad hoc Expert Panel
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association..
Castleman disease describes a group of heterogeneous clinicopathological disorders now included in the tumor-like lesions with B-cell predominance of the World Health Organization classification. Managing idiopathic multicentric Castleman disease (iMCD) is challenging, because few systematic studies or comparative randomized clinical trials have been conducted. International, consensus evidence-based guidelines for iMCD were published in 2018, but gaps in the therapeutic options for difficult-to-treat patients, who do not respond to siltuximab and other conventional therapies, still exist. This article presents the results of group discussion among an ad hoc constituted Panel of Italian experts to identify and address unmet clinical needs (UCNs) in managing iMCD. Recommendations on the appropriateness of clinical decisions and proposals for new research concerning the identified UCNs were issued through formalized multiple-step procedures after a comprehensive analysis of the scientific literature. The following key UCNs were addressed: strengthening the diagnostic certainty in iMCD patients before planning first-line therapy; management of siltuximab therapy; choice and management of immune-modulating, or chemotherapy agents in patients resistant/intolerant to siltuximab therapy. While most of the conclusions reached by the Panel are consistent with the existing guidelines, some alternative therapeutic options were stressed, and the discussion contributed to bringing forth the issues that need further investigation. Hopefully, this comprehensive overview will improve the practice of iMCD and inform the design and implementation of new studies in the field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
HemaSphere - 7(2023), 6 vom: 13. Juni, Seite e891 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zinzani, Pier Luigi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.06.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1097/HS9.0000000000000891 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357370961 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357370961 | ||
| 003 | DE-627 | ||
| 005 | 20231226072440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HS9.0000000000000891 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357370961 | ||
| 035 | |a (NLM)37234822 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zinzani, Pier Luigi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease |b A Consensus-based Position Paper From an ad hoc Expert Panel |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.06.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. | ||
| 520 | |a Castleman disease describes a group of heterogeneous clinicopathological disorders now included in the tumor-like lesions with B-cell predominance of the World Health Organization classification. Managing idiopathic multicentric Castleman disease (iMCD) is challenging, because few systematic studies or comparative randomized clinical trials have been conducted. International, consensus evidence-based guidelines for iMCD were published in 2018, but gaps in the therapeutic options for difficult-to-treat patients, who do not respond to siltuximab and other conventional therapies, still exist. This article presents the results of group discussion among an ad hoc constituted Panel of Italian experts to identify and address unmet clinical needs (UCNs) in managing iMCD. Recommendations on the appropriateness of clinical decisions and proposals for new research concerning the identified UCNs were issued through formalized multiple-step procedures after a comprehensive analysis of the scientific literature. The following key UCNs were addressed: strengthening the diagnostic certainty in iMCD patients before planning first-line therapy; management of siltuximab therapy; choice and management of immune-modulating, or chemotherapy agents in patients resistant/intolerant to siltuximab therapy. While most of the conclusions reached by the Panel are consistent with the existing guidelines, some alternative therapeutic options were stressed, and the discussion contributed to bringing forth the issues that need further investigation. Hopefully, this comprehensive overview will improve the practice of iMCD and inform the design and implementation of new studies in the field | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Paulli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Arcaini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Della Torre, Emanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrero, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Figuera, Amalia |e verfasserin |4 aut | |
| 700 | 1 | |a Frigeri, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Martelli, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Sabattini, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpa, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Barosi, Giovanni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d 2017 |g 7(2023), 6 vom: 13. Juni, Seite e891 |w (DE-627)NLM29509902X |x 2572-9241 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:6 |g day:13 |g month:06 |g pages:e891 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HS9.0000000000000891 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 6 |b 13 |c 06 |h e891 | ||